Every 424B that Lantern Pharma Inc. (LTRN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LTRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTRN filings page.
Lantern Pharma Inc. (LTRN) is offering 1,469,725 common shares at $1.09 each and, for qualifying purchasers in lieu of shares, pre-funded warrants to purchase up to 2,200,000 shares at $1.0899 per warrant; the underlying shares are also registered. The pre-funded warrants carry a $0.0001 exercise price and are immediately exercisable, with a 4.99% beneficial-ownership limit (or 9.99% at the holder’s election).
Lantern estimates net proceeds of approximately $3.60 million after placement-agent fees and estimated expenses, assuming the sale of all common shares offered and no exercise of purchase warrants; it intends to use the proceeds for working capital and general corporate purposes. A concurrent private placement includes purchase warrants to buy up to 3,669,725 shares at $1.09 each; exercise is subject to stockholder approval, and cash proceeds would arise only from cash exercise.
Lantern disclosed substantial doubt about its ability to continue as a going concern absent additional funding. Working capital as of June 30, 2026 included about $7.36 million in cash, cash equivalents and marketable securities; separately, Lantern believes these resources as of the supplement date, including net proceeds, will not fund operating expenses and capital expenditures for 12 months. Nasdaq notified it that listed-securities market value had been below $35 million for 30 consecutive business days; its compliance deadline is March 24, 2027.
Lantern Pharma Inc. is offering 1,454,175 shares of common stock at $2.06 per share. The offering also includes pre-funded warrants to purchase up to 681,748 shares (exercise price $0.0001) available to purchasers who would otherwise exceed 4.99% (or elect 9.99%) ownership limits.
In a concurrent private placement, Lantern is issuing purchase warrants to buy up to 2,135,923 shares at an exercise price of $2.27 (not registered here). Gross proceeds from the registered component are $4,399,933.20 and estimated net proceeds to Lantern, before expenses, are approximately $4.09 million; Lantern estimates net proceeds after fees and expenses of approximately $3.94 million for use as working capital and general corporate purposes.
Lantern Pharma Inc. filed a preliminary prospectus supplement to offer shares of its common stock in a best-efforts placement led by ThinkEquity LLC. The supplement discloses that there is no minimum offering amount, placement agent fees and placement agent warrants equal to 3% of shares sold, and that proceeds will be used for working capital and general corporate purposes.
The company reports a public float of $35,164,013 based on 11,208,938 shares, 11,254,687 shares outstanding as of December 31, 2025, total assets of approximately $11.04M, and working capital of approximately $6.5M. The filing notes ongoing clinical programs for LP-300, LP-184 and LP-284 and planned FDA Type C meeting for proposed HARMONIC study amendments.